CAR T-cell therapy is a highly effective treatment option in hematologic malignancies by targeting cancer cells and destroying them.
CAR T-cell therapy identifies cancer through a process that involves engineering T cells to recognize and target specific cancer cell markers. Here’s how it works:
- Engineering T Cells: T cells are collected from the patient’s blood and genetically modified in the laboratory to express chimeric antigen receptors (CARs) on their surface. These CARs are designed to bind to specific antigens found on the surface of cancer cells.
- Targeting Cancer Cells: The CARs on the engineered T cells are tailored to recognize unique proteins or markers (antigens) present on the cancer cells. This specificity allows the CAR T cells to selectively bind to and identify cancer cells while largely ignoring normal, healthy cells.
- Activation and Attack: Once the CAR T cells are infused back into the patient, they seek out and attach to the cancer cells through the CARs. This binding activates the T cells, triggering them to destroy the targeted cancer cells through various mechanisms, including releasing cytotoxic substances that induce cell death.
- Persistence and Surveillance: The engineered T cells can persist in the body and continue to recognize and eliminate cancer cells over time, offering ongoing surveillance and protection against cancer recurrence.
In summary, CAR T-cell therapy identifies cancer by equipping T cells with receptors that specifically target and bind to cancer cell markers, enabling a focused and effective immune attack on the tumor.
